Replies to post #218073 on Biotech Values

[DewDiligence]

Mavyret’s US market share—week ending 3/23/18 (according to IMS):

• ABBV/ENTA’s NRx share=43.3%, the highest-ever weekly figure, edging the old high of 43.1% in the week ending 3/9/18.

• ABBV/ENTA’s TRx share=37.2%, up slightly from 36.6% in the previous week, but 100 basis points shy of the highest-ever weekly figure of 38.2% in the week ending 3/9/18.

(Almost all of ABBV/ENTA’s US HCV business now comes from Mavyret.)